In general, SPCG has been active with clinical research, reorganisation and international collaboration over the last two years.

SPCG Board

We have held the yearly meeting in January at Arlanda. We now have Uro-Oncologists as ordinary members in our board, one from each country. Oncologists thereby are involved in the board in a new way and our secretary is now Henriette Lindberg, an Oncologist from Denmark. Recruitment to the board has been successful from most countries, but we are still lacking participation from Norway. The responsibility for the economy and signing for SPCG has been taken over by the Chairman Göran Ahlgren from PO Hedlund. The accounting is now hired in Malmö while the Revisor still is in Stockholm.

Progress in SPCG Studies

SPCG 4 has reported an update, again published in a highly ranked journal. This illustrates that studies in prostate cancer can generate scientific publications more than 20 years after initiation.

SPCG 5 is now considered finally closed.

SPCG 6 has a revival, the database was taken over from Astra-Zeneca. The patient cohort were updated regarding survival and analysed with a median follow up 14,6 years when 71% of the patients has died.

SPCG 7 has been updated and shows now a almost 20% difference in mortality. This is definitely a landmark study.

SPCG 11 has been published in European Journal of Urology as a negative study.

SPCG 12 is now mature for the final analysis in 2015. Work is ongoing. It is the world’s largest study on adjuvant chemotherapy after radical prostatectomy for high risk patients. There is a lot of interest in the study as chemotherapy in early metastatic disease has been shown to prolong survival.

SPCG 13 Follow up is ongoing and final analysis planned in 2017.

SPCG 14 has had a slow recruitment in randomising patients with rising PSA to bicalutamide +/- chemotherapy. Approximately 250 patients has been recruited and will continue at least this year.

SPCG 15 has finally started recruitment. Twenty patients has been randomised in three different sites in Sweden. Another trial meeting will take part in September. The study board has done an excellent job.

SPCG 16 is now a protocol with patients progressing on bicalutamide, that will be randomised either to ADT or one of the new hormonal treatments as monotherapy. The study is still planned.
SPCG 17 is a protocol planned from Uppsala, it is on Active Surveillance where patients are suggested treatment based on present criteria or on strict criteria on more progressive disease. An invitation to participate has been sent out.

SPCG Trial meeting

In October 2014 the 4th Trial meeting was held in Malmö with 60 participants. The focused the SPCG 15 protocol and was considered as the start meeting. Aspects on treatment of locally advanced Prostate Cancer was discussed as well as the protocol and CRF in detail. This year the meeting was held at Skåne University Hospital and was a success for fruitful discussions around SPCG 15 and the other ongoing studies that also were updated.

SPCG Research Grant

From Ing-Britt and Stig Mårtensson foundation, a yearly Grant of 50 000 SEK is awarded to Clinical Research after application. Two Grants for 2013 and 2014 has been delivered. Last year, there were six applicants. The winner was from Finland and we now have award winners from Denmark, Norway and Finland. There is a new Grant announced for 2015.

Economy

Support has been given to start the SPCG 15 study for meetings and applications. However, studies must be financed as much as possible in cooperation with the industry and through external applications as far as possible. There is 150 000 SEK yearly to support new protocols and analysis if applications to other sources is unsuccessful. The economy is stable and gives room for the necessary meetings for the board.

Honorary members

P-O Hedlund who was one of the founders of SPCG and was elected as an Honorary Member at the board meeting in 2014. A book was given as a gift for his fantastic work with SPCG.

Malmö June 2015

Göran Ahlgren
Chairman